Anil Sethi, Founder Citizen and ‘Big Thoughts About Small Data’ session chair at PMWC 2018 Silicon Valley: “We’ll do well, by doing good. Together!”

Anil Sethi lost his little sister Tania on September 11, 2017 to metastatic breast cancer and through that experienced the caregiver’s journey, firsthand. Anil has an interesting background: investor, mHealth lecturer and mentor to StartX, UCSF, Cancer Commons, and past board member of Johns Hopkins Medical School/SON. He has been working in healthcare as a serial entrepreneur since many years founding several startups with the vision to address the data access problem in healthcare. His most recent endeavor was Gliimpse – a secure data platform that attempts to solve the problem of medical data aggregation and standardization, and provide a platform where consumers can share their own medical records and other information – which he co-founded in 2013 and was subsequently bought by Apple in 2016.

We had an opportunity to discuss with Anil the session he has planned for PMWC 2018 Silicon Valley, January 22-24. Here is what he had to say:

Anil Sethi: “It’s fine to talk about cutting edge immunotherapy, biomarkers for early detection of disease, and the implications of ‘big data’. But there are dirty little secrets surrounding big-data in healthcare…. we’ve got to think much smaller. Small data; N-of-1; The individual. Collected patient by patient, seven billion times over.”

HIPAA-leveraged access to your own health data to facilitate and enhance your clinical treatment and enable a broad ‘donate-your-data’ (DYD) ecosystem is expected to help speed up the advancement of research and development of therapeutics targeted to cure diseases, starting with cancer. Simply working forward from wet chemistry in the traditional approach is too slow. Though well intentioned, it’s limited in its ability to directly impact the lives of those in need, today. As Steve Jobs would say, “No no no, we’re thinking about this all wrong.” With so much at stake, affecting so many directly and indirectly, we must think differently. Let’s enroll all the world’s citizens in our fight against diseases, starting with cancer.

If computational biology is meant to successfully empower clinical and research initiatives in our fight against cancer, it must intersect with data gathered from citizens living in every corner of our planet. Liquid biopsies, big data, AI and Machine Learning are amazing advances spread across the technology axis. Yet, real change will only come at the intersection of technology and the human axis. When paired with actual people, computational medicine can become a reality at the intersection of science and patients, researchers and clinicians.

The track spearheaded and co-organized by Anil addresses the challenges of patient data access, self-reported data, and regulatory solutions serving both human and AI/ML computational needs and will outline a different way of thinking about the future. In essence, the proposal offers a different plan of attack on cancer that will empower people, patients, and professionals. The first hour promises four exciting 15 minutes presentations followed by a provocative Q&A session with the same panelists.

Session #1: A patient-mediated mHealth solution to legally collecting and sharing clinical data

Presenter: Anil Sethi

Physicist Max Planck suggested, “in the correct formulation of the question lies the key to the ‘correct’ answer.” The healthcare industry continues their slog in trying to control siloed patient data. They continue to ask incorrect questions and thus miss the key that connects better outcomes with lower costs—the patient. We’ll discuss the specifics of a model of patient mediated data collection and sharing, and how patients may be the key to accelerating and unlocking genomic data for curative discoveries.

Session #2: Regulatory implications and a practical understanding of patient data access and sharing  

Presenter: Deven McGraw

HIPAA gives patients a right to copies of their health information – including a right to have that data forwarded anywhere – to another treatment provider, a caregiver, or a research initiative. This right is reinforced by financial incentives (such as “meaningful use,” MACRA, and other outcomes or value-based payment initiatives) that reward the sharing of data with patients. We’ll clarify patient access rights as well as security and privacy, looking specifically at how physicians, researchers, and institutions can increase patient engagement while benefiting from data donations in return.

Deven McGraw previously served as the Deputy Director for Health Information Privacy at the HHS Office for Civil Rights (OCR) and the acting Chief Privacy Officer for the Office of the National Coordinator (ONC) for Health Information Technology. In that capacity, Deven was the chief regulatory guidance and compliance officer for HIPAA in the United States. Deven also advised PCORNet (the Patient Centered Outcomes Research Network), as well as the federal All of Us Research Initiative, on HIPAA and patient donated data research initiatives.

Session #3: An informatics driven data-model for the semantic interoperability around cancer 

Presenter: Brian Carlsen

The previous sessions have addressed why patients are the natural solution to solve data sharing and why federal policies can be leveraged for same. However, having an API (e.g. HL7-FHIR) only solves the syntax problem. There continues to be a semantic mismatch between health data elements such as lab results where some reporting systems may call it Hemoglobin while others call the same element HGB or Hemob, and standard health terminologies may call it something else. Cancer serves as our backdrop to illustrate semantically matching like-terms in service of computational and ML/AI data needs.

Brian Carlsen is a clinical terminologist, previously for Apple Health. An advisory group member of SNOMED, he was an architect of the NLM’s UMLS and the NCI Metathesaurus, designed to help solve for semantically interoperable health records. He’s a software developer of web-based and open source tools for the leveraging of clinical terminologies across healthcare domains including labs and medications. He is an expert in creating computable representations of health data as a consistent way to index, store, retrieve, and aggregate medical data across payers, providers, and consumer devices.

Session #4: Partnering directly with patients to accelerate translational cancer research

Presenter: Tania Simoncelli

We discuss the value of computationally accurate health records shared from extraordinary responders to help develop methods for precisely matching patients to new drugs or new therapies. The implications of both large numbers and outliers, to move from 5% cancer patient enrollment to 80% enrollment is an exciting possibility. And how technology, social media and cultural changes now provide a new opportunity to engage cancer patients and directly partner them with researchers.

In 2005, Tania Simoncelli spearheaded the development of the ACLU’s successful lawsuit challenging the patenting of the BRCA genes (AMP v. Myriad, decided by the U.S. Supreme Court in 2013).  She has continued to champion open science and the rights of patients to access their own health information ever since, through policy roles at the FDA and the White House Office of Science and Technology Policy, as Executive Director of the Count Me In initiative at the Broad Institute, and in her new role as Director of Policy for Science at the Chan Zuckerberg Initiative.

Hear from 300 speakers and 60 sessions in 5 tracks: Program

Interview with Gabriel Bien-Willner of Palmetto GBA

Q: What does your role entail as the director of the MolDX program at Palmetto GBA?

A: The job directing MolDX is multifaceted; first and foremost the MolDX program is responsible for assessing molecular diagnostic tests on the market and makes coverage and pricing determinations for such tests and technology. This is usually done through local coverage determination policies or technical assessments.

Read More

Interview with Peter Marks of FDA

Q: The CBER’s Regenerative Medicine Advanced Therapy Designation program has been very successful, with about 100 requests for designation in the two years of its existence. Can you please tell us about the program and how it was put together?

A: The Regenerative Medicine Advanced Therapy (RMAT) Designation program came into being as part of the 21st Century Cures Act that was signed into law on December 13, 2016.

Read More

Interview with Calum MacRae of Harvard Medical School

Q: What patient data do we need to better understand the underlying cause of disease and how to prevent it?

A: Medicine at present is highly underdetermined and data poor. To be precise, one must be comprehensive, so medicine (with our consent) will use not only what we currently conceive of as biomedical information, but also data from across our lives.

Read More

Headlines from PMWC 2019 Silicon Valley

A big ‘Thank You’ to all of our presenters and attendees for celebrating 10 years of precision medicine progress with us! PMWC 2019 Silicon Valley was attended by 2000 participants from 35 countries, which included over 400 speakers in 5 parallel tracks!

Read More

Interview with Ken Bloom of Ambry Genetics

Q: Tell us more about your organization/company. What patient population are you serving and which services are you specializing in?

A: Ambry Genetics is a recognized leader in high quality complex genetic testing. We seek to find the genomic cause or contributors to rare diseases, abnormal phenotypes and hereditary disorders.

Read More

Interview with Lee Pierce of Sirius Computer Solutions

Q: What is the state of big data and analytics in healthcare, and how to best use the reams of data available?

A: More than ever, Healthcare organizations are achieving measurable value through use of their data and analytics assets. There is more raw material available than ever to create value. This raw material is the data flowing from internal systems and applications and also from devices and systems external to healthcare organizations.

Read More

Interview with Anita Nelsen of PAREXEL

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: Today’s emerging technologies are making the promise of individualized treatment a reality.

Read More

Interview with Ilan Kirsch of Adaptive Biotechnologies

Q: The Nobel Prize in Medicine was awarded recently to James Allison and Tasuku Honjo for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” What is your first-hand experience the impact that those new drugs had on patients?

A: For decades cancer was viewed as solely a cell-autonomous condition.

Read More

BMS buys Celgene | Lilly buys Loxo Oncology – Does this Signal a Return to Strong Deal-Making Activities in 2019?

Bristol-Myers Squibb’s blockbuster $74B deal to buy Celgene creates an oncology powerhouse amid industrywide excitement about the rapidly evolving science and explosive growth of the sector. The agreement could signal a return to deal-making for the pharmaceutical industry in the $133B global oncology therapeutics market.

Read More

Interview with Gini Deshpande of NuMedii

Q: What need is NuMedii addressing?

A: NuMedii, has been pioneering the use of Big Data, artificial intelligence (AI) and systems biology since 2010 to accelerate the discovery of precision therapies to address high unmet medical needs. Artificial Intelligence approaches are a natural fit to harness Big Data as they provide a framework to ‘train’ computers to recognize patterns and sift through vast amounts of new and existing genomic

Read More

Interview with Minnie Sarwal of UCSF

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: Completion of complete sequence data from the human genome project, and the advances in proteomic, microRNA and epigenetic assays added a layer of pathway biology to the understanding of human diseases.

Read More

Interview with Shidong Jia of Predicine

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling for clinical Dx. How soon, do you think, will we see accelerated growth and what can we expect?

A: We will see accelerated human genome profiling for clinical Dx in 2019 and the coming years as more biomarker-based cancer drugs are gaining approval.

Read More

Interview with Iya Khalil of GNS Healthcare

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I think that there’s a lot of speculation and uncertainty around AI, but I don’t foresee a time when we won’t need physicians.

Read More

Interview with Ilya Michael Rachman of Immix Biopharma Inc.

Q: The Nobel Price in Medicine was awarded recently to James Allison and Tasuku for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” Besides CAR T-cell therapy what do you think next generation immunotherapies will look like to successfully combat cancer?

A: The next generation of immunotherapies will build on the insights discovered by immunologists like James Allison and Tasuku Honjo and extend them to modify the body’s response to tumors.

Read More

Join me to Kick off PMWC Silicon Valley in the Santa Clara Convention Center, Focusing on Every Element of Precision Medicine

My team worked in collaboration with Bill Dalton, Kim Blackwell, Atul Butte / India Hook Barnard, Nancy Davidson and Sharon Terry to create a program that touches every component of precision medicine while bringing together all of its key stakeholders. Leading participating institutions including Stanford Health Care, UCSF, Duke Health, Duke University, John Hopkins University, University of Michigan and more will share their learnings and experiences and their successes and challenges, as they make precision medicine the new standard of care for all.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 17th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 21-24, 2020. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

See 2019 Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

See 2019 Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).